Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal The Journal of Indonesia Sustainable Development Planning (JISDeP) Jurnal Ilmu Kesehatan dan Gizi
Evi Sylvia Nurrasjid
Unknown Affiliation
Economics, Econometrics & Finance Energy Environmental Science Health Professions Law, Crime, Criminology & Criminal Justice Social Sciences

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Kajian Risiko pada Proses Penyimpanan dan Pendistribusian Bahan Baku di Gudang Industri Farmasi dengan Pendekatan Metode Failure Mode and Effect Analysis Hanif Azhar Musyaffa; Mas Rahman Roestan; Evi Sylvia Nurrasjid; Iwa Kustiyawan
Jurnal Ilmu Kesehatan dan Gizi Vol. 2 No. 3 (2024): Juli : Jurnal Imu Kesehatan dan Gizi
Publisher : Pusat Riset dan Inovasi Nasional

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55606/jig.v2i3.3149

Abstract

Quality risk management is one of the important things in quality control in a pharmaceutical industry. One of the risky activities in the pharmaceutical industry is in storage and distribution. Every activity carried out in the inventory warehouse can potentially cause risks that affect quality including the flow of the storage and distribution process of goods. Based on this, a study was conducted in the form of a risk assessment on the flow of the storage and distribution process of release goods in the inventory warehouse of a pharmaceutical industry in Bandung which aims to determine the level of risk that has the potential for failure. The FMEA (Failure Modes and Effects Analysis) method is a method that can be used to assess the risks that can occur in the flow of the storage and delivery process of goods in the warehouse. This risk assessment is carried out with the stages of risk identification, risk analysis, and risk evaluation using categorization based on the Risk Priority Number (RPN). In this study, 15 risks were obtained with details of 1 low category risk, 7 medium category risks, 6 high category risks, and 1 very high category risk. Therefore, the pharmaceutical industry can immediately determine mitigation steps and take control measures against risks in the high and very high categories to reduce the risk of failure with the hope that the quality, safety and efficacy of the product can be maintained properly
Models of Research Collaboration to Support the Self-Reliance of Indonesia’s Pharmaceutical Industry Pratistha, Brian; Evi Sylvia Nurrasjid; Amin Nurhuda; Endang Sulastri; Muniha Hikmah; Ahmad Syafiq Kamil
The Journal of Indonesia Sustainable Development Planning Vol 7 No 1 (2026): April
Publisher : Pusbindiklatren Bappenas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.46456/jisdep.v7i1.986

Abstract

Promoting a self-reliant pharmaceutical industry constitutes one of the national strategic agendas. The government undertakes efforts toward self-sufficiency to strengthen health resilience and advance Indonesia’s economic transformation. This policy paper aims to formulate an integrated research collaboration model designed to enhance research and development capacity, increase domestic production capability, and reduce dependence on imported pharmaceutical raw materials and products. The research methodology encompasses an analysis of relevant policies and regulations, a comparative study of three countries considered to have more advanced pharmaceutical sectors, and a mapping of key actors and interaction mechanisms within the pharmaceutical research and innovation ecosystem. The problem identification findings indicate that current challenges include limited inter-institutional coordination, weak technology transfer mechanisms, and the suboptimal alignment between research funding and incentives with industry needs. This policy paper further finds that a primary prerequisite for mission-oriented research collaboration is the presence of a jointly agreed strategic vision among stakeholders, supported by collaborative funding schemes and adaptive intellectual property governance arrangements. The resulting policy recommendations emphasize the need to strengthen the role of the state as an orchestrator of collaboration and to ensure closer integration between research initiatives and pharmaceutical industrialization policies.
Co-Authors Ahmad Syafiq Kamil Amin Nurhuda Endang Sulastri Hanif Azhar Musyaffa Iwa Kustiyawan Mas Rahman Roestan Muniha Hikmah Pratistha, Brian